Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rizatriptan for Vestibular Migraine
NCT02447991Phase 3Completed
- Start
- Dec 2014
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vestibular migraine (VM) comparing Placebo with Rizatriptan (2 arms). Primary endpoints: Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild at 1 hour and Episodes With Symptoms of Unsteadiness/Dizziness Reduced From Moderate/Severe to None/Mild at 1 hour. Started Dec 2014; status: completed.
02
Drugs
rizatriptan
03
Conditions
vestibular migraine (VM)
Beyond the preview
Go deeper on NCT02447991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447991.